Verrica Pharmaceuticals, Inc. (VRCA)
4.10
-0.08
(-1.91%)
USD |
NASDAQ |
Oct 09, 16:00
4.10
0.00 (0.00%)
After-Hours: 19:11
Verrica Pharmaceuticals EPS Diluted (Quarterly) : -0.6174 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.6174 |
| March 31, 2026 | -0.4544 |
| December 31, 2025 | -0.5722 |
| September 30, 2025 | -0.0289 |
| June 30, 2025 | 0.0215 |
| March 31, 2025 | -0.1027 |
| December 31, 2024 | -2.406 |
| September 30, 2024 | -0.4884 |
| June 30, 2024 | -0.3696 |
| March 31, 2024 | -0.4374 |
| December 31, 2023 | -0.5315 |
| September 30, 2023 | -0.5383 |
| June 30, 2023 | -0.2394 |
| March 31, 2023 | -0.1532 |
| December 31, 2022 | -0.1444 |
| September 30, 2022 | 0.0019 |
| June 30, 2022 | -0.3695 |
| March 31, 2022 | -0.3078 |
| December 31, 2021 | -0.3467 |
| Date | Value |
|---|---|
| September 30, 2021 | -0.4662 |
| June 30, 2021 | -0.428 |
| March 31, 2021 | -0.0366 |
| December 31, 2020 | -0.5178 |
| September 30, 2020 | -0.4196 |
| June 30, 2020 | -0.3769 |
| March 31, 2020 | -0.3934 |
| December 31, 2019 | -0.3064 |
| September 30, 2019 | -0.2446 |
| June 30, 2019 | -0.2814 |
| March 31, 2019 | -0.3009 |
| December 31, 2018 | -0.305 |
| September 30, 2018 | -2.377 |
| June 30, 2018 | -9.245 |
| March 31, 2018 | -6.479 |
| December 31, 2017 | -2.621 |
| September 30, 2017 | -0.0529 |
| June 30, 2017 | -0.0426 |
| March 31, 2017 | -0.0222 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 0.356 |
| Veru, Inc. | -0.3032 |
| Johnson & Johnson | 2.268 |
| Eli Lilly & Co. | 7.939 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -13.15M |
| Revenue (Quarterly) | 5.862M |
| Total Expenses (Quarterly) | 19.02M |
| Enterprise Value | 62.42M |
| Gross Profit Margin (Quarterly) | 85.02% |
| Profit Margin (Quarterly) | -224.4% |
| Earnings Yield | -40.80% |
| Normalized Earnings Yield | -39.78 |